Benzinga's Top #PreMarket Gainers
December 24, 2013 at 08:09 AM EST
Supernus Pharmaceuticals (NASDAQ: SUPN ) soared 18.24% to $8.75 in the pre-market trading after the company confirmed the FDA approval of its partner's heart blood-pressure treatment. Boston Properties (NYSE: BXP ) surged 5% to $108.67 in the pre-market session. Boston Properties shares have dropped 1.81% over the past 52